This company develops bioelectronic medicines that target specific genes to accelerate bone fracture healing and treat musculoskeletal injuries, osteoarthritis, osteoporosis, and cancer. Their technology harnesses the body's natural self-repair mechanisms to address the root causes of these conditions.
Funding
Funding not disclosed
Founders
Product
Problem
Current treatments for bone fractures, musculoskeletal injuries, osteoarthritis, osteoporosis, and cancer often fail to fully address the underlying causes and can be slow to promote healing. These conditions can significantly impact patients' quality of life and require innovative therapeutic approaches.
Solution
Vira Regen is developing gene-specific electroceuticals designed to accelerate healing and address the root causes of musculoskeletal conditions and cancer. Their approach leverages the body's natural self-repair mechanisms by stimulating the bioelectric network and genetic code. By using computational biology and bioinformatics methods, Vira Regen identifies noninvasive gene therapies and tissue stimulation signatures to promote regeneration.
Target Audience
The primary target audience includes patients suffering from bone fractures, musculoskeletal injuries, osteoarthritis, osteoporosis, and cancer, as well as healthcare providers seeking advanced regenerative medicine solutions.
Features
- Gene-specific electroceuticals for targeted therapy
- Non-invasive approach to stimulate tissue regeneration
- Computational biology and bioinformatics methods for identifying therapeutic targets
- Focus on bone fracture healing, musculoskeletal injuries, osteoarthritis/osteoporosis, and cancer